These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 37495171)

  • 21. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 23. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
    Singh A; Daemen A; Nickles D; Jeon SM; Foreman O; Sudini K; Gnad F; Lajoie S; Gour N; Mitzner W; Chatterjee S; Choi EJ; Ravishankar B; Rappaport A; Patil N; McCleland M; Johnson L; Acquaah-Mensah G; Gabrielson E; Biswal S; Hatzivassiliou G
    Clin Cancer Res; 2021 Feb; 27(3):877-888. PubMed ID: 33077574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
    Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MM; Janne PA; Van Allen EM; Barbie DA; Vokes NI
    Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
    Rosellini P; Amintas S; Caumont C; Veillon R; Galland-Girodet S; Cuguillière A; Nguyen L; Domblides C; Gouverneur A; Merlio JP; Bezin J; Girodet PO
    Eur J Cancer; 2022 Sep; 172():85-95. PubMed ID: 35759814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring
    Nie W; Gan L; Wang X; Gu K; Qian FF; Hu MJ; Zhang D; Chen SQ; Lu J; Cao SH; Li JW; Wang Y; Zhang B; Wang SY; Li CH; Yang P; Xu MD; Zhang XY; Zhong H; Han BH
    Oncoimmunology; 2021 Jan; 10(1):1865670. PubMed ID: 33537171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer.
    Hasegawa T; Yanagitani N; Ninomiya H; Sakamoto H; Tozuka T; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Ariyasu R; Uchibori K; Kitazono S; Horiike A; Nishio M
    In Vivo; 2020; 34(5):2997-3003. PubMed ID: 32871843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.
    Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS
    Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
    Koyama S; Akbay EA; Li YY; Aref AR; Skoulidis F; Herter-Sprie GS; Buczkowski KA; Liu Y; Awad MM; Denning WL; Diao L; Wang J; Parra-Cuentas ER; Wistuba II; Soucheray M; Thai T; Asahina H; Kitajima S; Altabef A; Cavanaugh JD; Rhee K; Gao P; Zhang H; Fecci PE; Shimamura T; Hellmann MD; Heymach JV; Hodi FS; Freeman GJ; Barbie DA; Dranoff G; Hammerman PS; Wong KK
    Cancer Res; 2016 Mar; 76(5):999-1008. PubMed ID: 26833127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.
    Cai R; Zhu H; Liu Y; Sha H; Peng W; Yin R; Zhou G; Fang Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10027-10040. PubMed ID: 37261523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Probing Mutant KRAS, STK11, KEAP1 in NSCLC.
    Cancer Discov; 2022 Oct; 12(10):2226. PubMed ID: 35997519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
    Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
    Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of
    Padda SK; Aredo JV; Vali S; Singh NK; Vasista SM; Kumar A; Neal JW; Abbasi T; Wakelee HA
    JCO Precis Oncol; 2021 Nov; 5():153-162. PubMed ID: 34994595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies.
    Qian J; Nie W; Lu J; Zhang L; Zhang Y; Zhang B; Wang S; Hu M; Xu J; Lou Y; Dong Y; Niu Y; Yan B; Zhong R; Zhang W; Chu T; Zhong H; Han B
    Int J Cancer; 2020 Jun; 146(11):3124-3133. PubMed ID: 31583695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TCR Repertoire Diversity of Peripheral PD-1
    Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
    Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
    Della Corte CM; Sen T; Gay CM; Ramkumar K; Diao L; Cardnell RJ; Rodriguez BL; Stewart CA; Papadimitrakopoulou VA; Gibson L; Fradette JJ; Wang Q; Fan Y; Peng DH; Negrao MV; Wistuba II; Fujimoto J; Solis Soto LM; Behrens C; Skoulidis F; Heymach JV; Wang J; Gibbons DL; Byers LA
    J Thorac Oncol; 2020 May; 15(5):777-791. PubMed ID: 32068166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.